Does Mirtazapine Cause Orthostatic Hypotension?
Yes, mirtazapine can cause orthostatic hypotension, though it occurs infrequently in clinical practice. The FDA drug label explicitly states that mirtazapine was associated with significant orthostatic hypotension in early clinical pharmacology trials with normal volunteers, though it was observed infrequently in clinical trials with depressed patients 1.
Mechanism and Clinical Evidence
Mirtazapine's orthostatic hypotensive effects are explained by its antagonism of peripheral α1-adrenergic receptors and histamine (H1) receptors 1. This pharmacologic profile creates a theoretical risk for blood pressure drops upon standing.
The actual clinical incidence appears relatively low compared to other antidepressants. In the comprehensive safety review of mirtazapine's clinical trial program, orthostatic hypotension was not listed among the adverse effects that occurred significantly more frequently than placebo 2. The most common side effects were drowsiness (23% vs 14% placebo), sedation (19% vs 5%), dry mouth (25% vs 16%), increased appetite (11% vs 2%), and weight gain (10% vs 1%) 2.
Comparative Risk Among Antidepressants
A 2018 matched cohort study in older adults (≥50 years) found that selective serotonin reuptake inhibitors (SSRIs) were associated with orthostatic hypotension at an odds ratio of 2.11, but mirtazapine specifically was not found to have a statistically significant association with orthostatic hypotension in their analysis 3. This suggests mirtazapine may carry lower risk than some other antidepressant classes, though the study noted it was not adequately powered to detect changes within all antidepressant subgroups.
A 2021 systematic review and meta-analysis of drug-induced orthostatic hypotension found that tricyclic antidepressants carried the highest risk (OR 6.30), while mirtazapine was not specifically highlighted as a high-risk agent 4.
Clinical Recommendations
Use mirtazapine with caution in patients with:
- Known cardiovascular or cerebrovascular disease that could be exacerbated by hypotension (history of myocardial infarction, angina, or ischemic stroke)
- Conditions predisposing to hypotension (dehydration, hypovolemia)
- Concurrent treatment with antihypertensive medications 1
Before prescribing mirtazapine, screen for orthostatic hypotension risk by:
- Having the patient sit or lie for 5 minutes
- Measuring blood pressure at 1 and/or 3 minutes after standing
- Defining orthostatic hypotension as a drop ≥20 mmHg systolic or ≥10 mmHg diastolic 5
Important Caveats
The 2024 ESC guidelines emphasize that when orthostatic hypotension is present in patients requiring treatment, the approach should be to switch medications that worsen orthostatic hypotension to alternative therapy rather than simply de-intensifying treatment 5. This is particularly relevant when mirtazapine is being used for depression in patients with cardiovascular disease.
Mirtazapine offers specific advantages in cardiovascular disease populations according to the 2024 AHA palliative care statement: it has been shown to be safe in patients with cardiovascular disease, offers additional benefits including appetite stimulation and sleep improvement, and may be preferable to other antidepressants that have more concerning cardiovascular profiles 6.
The elderly warrant particular attention, as they have 40% lower clearance (males) to 10% lower clearance (females) compared to younger patients, potentially increasing exposure to side effects including orthostatic hypotension 1. However, the safety profile in elderly patients in clinical trials was comparable to the overall population 2.
Bottom line: While mirtazapine can theoretically cause orthostatic hypotension through α1-receptor blockade, the clinical incidence appears lower than with tricyclic antidepressants and may be comparable to or lower than SSRIs. Monitor orthostatic vital signs before initiation and during titration, especially in elderly patients, those on antihypertensives, or those with cardiovascular disease. The drug's overall safety profile and additional benefits (appetite, sleep) may make it a reasonable choice when depression treatment is needed in patients at risk for orthostatic hypotension, provided appropriate monitoring is performed.